financetom
Business
financetom
/
Business
/
Why Genius Group (GNS) Stock Is Down 26%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Genius Group (GNS) Stock Is Down 26%
Aug 6, 2024 11:33 AM

Genius Group Ltd ( GNS ) shares are trading lower by 26.8% to $0.12 during Tuesday’s session after the company approved a 1-for-10 reverse stock split, effective on August 16.

The reverse stock split aims to increase the per share market price to meet the NYSE’s minimum price requirement. This decision was approved by shareholders on February 16, and the Board of Directors on August 5. Following the split, every ten shares will be consolidated into one share.

Adjustments will be made to exercise prices and share numbers in equity awards and incentive plans, but the number of authorized shares and their par value will remain unchanged.

Read Also: Jamie Dimon Confident In Economy As Markets Retreat: ‘We’re Going To Get Through It’

Should I Sell My GNS Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Genius Group ( GNS ) stock currently has an RSI of 5.35, indicating oversold conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

GNS has a 52-week high of $2.48 and a 52-week low of $0.11.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kazakhstan's Kashagan restored oil output on April 2, operator says
Kazakhstan's Kashagan restored oil output on April 2, operator says
Apr 2, 2024
ALMATY, April 3 (Reuters) - Output at Kazakhstan's giant Kashagan oilfield was fully restored on April 2 after a brief stoppage on April 1 caused by a fire or gas alarm which turned out to be false, the field's operator said on Wednesday. Sources told Reuters on Tuesday that output at the field, one of Kazakhstan's largest, fell to 30,342...
Taiwan's FPCC shuts Mailiao refinery port after quake, sources say
Taiwan's FPCC shuts Mailiao refinery port after quake, sources say
Apr 3, 2024
SINGAPORE, April 3 (Reuters) - Taiwan's Formosa Petrochemical (FPCC) has stopped operations at its port at the Mailiao refinery as a precautionary measure following a powerful earthquake, two people with knowledge of the matter said. The company is expected to resume operations at the port on Wednesday at around 3 p.m. (0700 GMT), one of the sources said. There could...
Japanese trading house Itochu expects 10% higher profit this financial year
Japanese trading house Itochu expects 10% higher profit this financial year
Apr 3, 2024
TOKYO (Reuters) - Japanese trading house Itochu ( ITOCF ) on Wednesday forecast a 10% rise in its net profit to 880 billion yen ($5.8 billion) this financial year, from an estimated 800 billion yen a year earlier, and expected a shareholder return ratio of 50%. Unveiling its new management plan for the 2024/25 financial year that started on April...
Genmab to Acquire ProfoundBio for $1.8 Billion
Genmab to Acquire ProfoundBio for $1.8 Billion
Apr 3, 2024
03:21 AM EDT, 04/03/2024 (MT Newswires) -- Genmab ( GMAB ) agreed to acquire privately owned biotechnology company ProfoundBio in an all-cash deal worth $1.8 billion, the companies said in a joint statement on Wednesday. The acquisition will give Genmab ( GMAB ) worldwide rights to ProfoundBio's portfolio of antibody-drug conjugates, comprising three candidates in clinical development, including rinatabart sesutecan,...
Copyright 2023-2025 - www.financetom.com All Rights Reserved